NASHVILLE, Tenn., March 6, 2020 /PRNewswire/ -- PMI Biopharma Solutions a provider of research, pharmaceutical development, and early-phase clinical manufacturing services and Nashville Biosciences, a clinical-genomic and bioinformatics company, today announced a strategic collaboration to leverage both parties' unique strengths to provide their customers with an integrated product offering around drug discovery and development.
Drug discovery is an expensive and high-risk endeavor, and proper target identification and validation is the foundation of a successful drug discovery campaign. Under this alliance, both organizations will have the opportunity to bundle Nashville Bioscience's data and in silico technology with PMI's comprehensive laboratory services and scientific expertise to experimentally test mechanistic & therapeutic hypotheses for a comprehensive drug target identification and validation package.
"With both organizations located in Nashville it was an easy decision to pair our capabilities to better serve our clients. This alliance will allow clients a smooth transition from in silico to in vitro studies," remarked Dr. David Sunseri, CEO, PMI Biopharma Solutions.
Dr. Leeland Ekstrom, Chief Operating Officer and Founder of Nashville Biosciences, commented, "Our respective capabilities fit together very nicely to advance our clients' research & development in the life sciences. We are excited to collaborate with PMI Biopharma Solutions to better serve our clients."
ABOUT PMI BIOPHARMA SOLUTIONS
PMI BioPharma Solutions offers manufacturing and aseptic fill & finish services along with protein science research services for clients in the pharmaceutical and biotechnology industries that seek to outsource individual projects, as well as engage in entire discovery campaigns. PMI BioPharma Solutions is especially positioned to provide comprehensive drug discovery support for small and virtual organizations. PMI BioPharma employs a highly skilled team of experienced professionals who can meet nearly any research or development challenge. Learn more at www.pmibio.com.
ABOUT NASHVILLE BIOSCIENCES
Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), was created to harness the Medical Center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities represented by BioVU®, one of the world's most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications. Learn more at www.nashville.bio
PMI BIOPHARMA SOLUTIONS:
Tom Genova, Director of Business Development
NASHVILLE BIOSCIENCES CONTACT:
James Stover, Chief Business Officer
SOURCE PMI Biopharma Solutions